Compare Ginkgo Bioworks Holdings Inc (DNA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs PulteGroup, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while PulteGroup, Inc. trades at $123.99 (market cap $23.73B). The key difference: PulteGroup, Inc. is far larger — about 40.2× Ginkgo Bioworks Holdings Inc's market cap, and PulteGroup, Inc. pays a 0.83% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | PHM | |
|---|---|---|
Market Cap | $590.53M | $23.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $142.56 |
52-Week Low | $5.48 | $108.00 |
Enterprise Value | $627.78M | $23.69B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
PulteGroup (PHM) trades at $123.75, down 0.8% on the day, with a bullish technical signal but mixed recent earnings. The stock shows strong profitability with a 12.14% net margin and attractive valuation at a P/E of 11.97. Recent news highlights new community developments and market sensitivity to mortgage rates. Cash flow trends improved in 2025 with net cash flow of $355 million.
Outlook remains cautiously optimistic with a consensus price target of $146, implying 18% upside. Risks include housing affordability pressures and recent earnings misses. Analyst sentiment is balanced with 45% buy ratings. The stock's valuation and dividend support a constructive view amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
